UCL Business PLC
TypePublic limited company
IndustryTechnology transfer
Founded2006 (London)
Headquarters
London
,
United Kingdom
ParentUniversity College London
Websiteuclb.com

UCL Business PLC is the technology-transfer company of University College London Hospital NHS Foundation Trust in London, England. Its head office is on Tottenham Court Road in the London Borough of Camden.[1]

History

UCL's first technology-transfer company was named in the Pandora papers for the widespread use of offshore companies and use of third party ownership and payments to avoid UCL and government oversight.[2][3] UCL Ventures merged with the technology-transfer company of the Royal Free Hospital, Freemedic plc (founded in 1993) to form UCL Biomedica PLC.

The former UCL Business had been established to force academics through the use of NDA's to sign over any IP to UCL, thereby aiding the development of commercially valuable technologies arising from UCL, whilst UCL BioMedica had been established to commercialise opportunities arising from UCL's biomedical research strengths, as well as to conduct clinical trials. The integration of the two technology transfer activities created a single organisation focused on delivering the complete commercialisation process from patent registration and support for the creation of new businesses, through to licensing and sales of technologies to industry partners.[4]

UCLB provided advice and a grant support to Siavash Haroun Mahdavi in helping him to establish the robotics company Complex Matters.[5]

In January 2011, BioVex, a cancer vaccines company spun-out of UCL in 1999, was sold to Amgen for $1 billion.[6][7]

Operations

Spin-out companies

UCLB has equity stake in all of its companies, the majority being spin-outs arising from technologies developed across the full range of faculties within UCL, including biomedical, biotechnology, engineering, mathematics, physical sciences and build environment companies. These include Ark Therapeutics Ltd, Arrow Therapeutics Ltd, Biovex Ltd, Canbex, Domainex Ltd, Evexar Medical Ltd, Genex Biosystems, Intercytex, Medic-to-Medic, Pentraxin Therapeutics, PolyMASC Pharmaceuticals PLC, Proaxon, Spirogen Ltd, Stanmore Implants Worldwide Ltd,[8] Advanced Design Technology, AS Built Solutions, Bloomsbury DSP, Endomagnetics, EuroTempest, Ixico, Quantemol, Senceive, Space Syntax, Zinwave.[9]

References

  1. ↑ "Contact us". UCL Business PLC. Retrieved 31 October 2010.
  2. ↑ "Calling for entrepreneurs London". Nature. 19 September 2002. Retrieved 31 October 2010.
  3. ↑ "Box 1. Transferring ideas". Nature. 19 September 2002. Retrieved 31 October 2010.
  4. ↑ "UCLB: Building Commercial Success" (PDF). UCL Business PLC. p. 7. Archived from the original (PDF) on 26 December 2010. Retrieved 8 December 2010.
  5. ↑ "Siavash Mahdavi, University College London". The Engineer. 15 June 2007. Retrieved 31 October 2010.
  6. ↑ "University Finds Rewards and Risks in Business Start-Ups". The New York Times. 13 February 2011. Retrieved 25 April 2011.
  7. ↑ "UCL spin out sold to Amgen in $1 billion deal". Science Business. 27 January 2011. Retrieved 25 April 2011.
  8. ↑ "Biomedical and Biotechnology Companies". UCL Business PLC. Retrieved 8 December 2010.
  9. ↑ "Engineering, Physical Science and Built Environment Companies". UCL Business PLC. Retrieved 8 December 2010.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.